BRIEF-Precision Therapeutics Subsidiary, Tumorgenesis, Announces License Agreement With 48Hour Discovery
March 15, 2018 at 16:31 PM EDT
* PRECISION THERAPEUTICS SUBSIDIARY, TUMORGENESIS, ANNOUNCES LICENSE AGREEMENT WITH 48HOUR DISCOVERY Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)
